Clinical-Grade HLA-Homozygous iPSC Banks for Transplantation: A Detailed Review

Introduction: The Critical Need for Cell Therapies

There is a global and critical demand for cells and tissues for transplantation in patients experiencing organ failure. Degenerative age-related human diseases are also increasingly impacting society, often with limited or no available treatments. Human-induced pluripotent stem cells (hiPSCs), derived from somatic cells, present a unique and promising solution by offering a virtually unlimited supply of a wide spectrum of specialized cells.

An alternative to using patient-specific hiPSCs is creating an allogeneic hiPSC collection from healthy donors. These cells could be expanded and differentiated to treat various patients. To minimize the risk of immune rejection, this collection must include hiPSC lines with sufficiently diverse and compatible homozygous Human Leukocyte Antigen (HLA) haplotypes, ensuring maximum possible population coverage.

HLA Compatibility: The Immune Challenge in Transplantation

What is HLA?

Having a compatible HLA haplotype implies a similarity or match between the Human Leukocyte Antigen (HLA) gene regions of two individuals. This compatibility is crucial in contexts such as organ transplantation, bone marrow (hematopoietic stem cell) transplants, and autoimmune disease risk assessment.

The HLA system comprises a group of genes located on chromosome 6. These genes encode proteins that are fundamental for the immune system's ability to distinguish between "self" and "non-self" cells. Each individual inherits one haplotype from each parent, meaning they possess two sets of HLA genes.

  • A haplotype refers to a group of alleles (gene variants) that are typically inherited together.
  • Common HLA genes of interest include HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP. (Crux and Elahi, 2017)

How is HLA Compatibility Determined?

HLA Typing involves DNA sequencing to precisely identify the alleles present in an individual.

HLA Matching quantifies compatibility by the number of matches across key loci (e.g., a 6/6 or 10/10 match). Compatibility is generally more probable among:

  • Siblings: Due to shared haplotypes inherited from common parents.
  • Individuals from the same ethnic background: Owing to a shared ancestral genetic background (e.g., Han Chinese or Ashkenazi Jew).

Example of a Perfect Match:

For instance, if two siblings undergo HLA typing, commonly assessed genes include HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1. A perfect match, such as a 10/10 match across these 5 loci (as demonstrated in the example where both donor and recipient have identical alleles for A, B, C, DRB1, and DQB1), signifies that these siblings share both haplotypes from each parent. This leads to:

  • A lower risk of immune rejection.
  • Better transplant outcomes.
  • A reduced need for immunosuppression.

Other Compatibility Examples:

  • An 8/10 or 9/10 match, indicating one or two mismatches, is often deemed acceptable in specific scenarios, such as for older patients or in less critical transplant procedures. These cases can still be considered "compatible" despite not being a perfect match.

Key Note: Beyond HLA alleles, other factors like minor histocompatibility antigens (e.g., HA-1, HA-2) and ABO blood group compatibility significantly influence transplant success.

Types of Transplants and HLA Matching Importance

The criticality of HLA matching varies depending on the type of transplant:

1. More Critical Transplants (HLA Matching is Essential)

These involve highly immunogenic tissues where HLA mismatching carries a very high risk of rejection.

  • Hematopoietic stem cell / bone marrow transplants (HSCT): The immune system itself is being replaced. Mismatching can lead to severe graft-vs-host disease (GVHD) or graft failure. It demands high-resolution, allele-level matching at loci like HLA-A, -B, and -C. Even a single mismatch can be perilous.

2. Moderately Critical Transplants (Matching is Important, but Some Mismatch is Tolerated)

  • Kidney transplants: HLA matching (particularly HLA-DR and HLA-B) significantly improves long-term survival. However, kidneys with some mismatches can still function with potent immunosuppressive therapy.
  • Pancreas transplants: Matching is beneficial but generally not as stringent as for bone marrow.

3. Less Critical Transplants (HLA Matching is Less Important)

These involve organs where the risk of rejection is not as closely tied to HLA compatibility.

  • Liver transplants: The liver is considered "immune-privileged" and exhibits a surprising tolerance for mismatches. ABO blood group compatibility is substantially more critical than HLA compatibility for liver transplantation.
  • Heart and lung transplants: While HLA mismatching increases rejection risk, the urgency of the transplant often prioritizes receipt of a suitable organ over perfect HLA matching. Immunosuppression is the primary strategy.
  • Corneal transplants: These are frequently performed without HLA matching due to the cornea's immune-privileged status.

Generating Clinically Acceptable iPSCs

Key Considerations for iPSC Production

Manufacturing scalable, unique, and standardized final cell products from homozygous haploselected hiPSCs, suitable for diverse diseases and clinical indications, is expected to reduce the cost of these products and the need for patient immune suppression. Cell derivatives sourced from HLA-matched hiPSC banks will facilitate the delivery of "off-the-shelf" cell therapy products, making them readily available for critical acute or subacute conditions, as well as for emerging diseases.

Establishing iPSCs suitable for clinical use involves specific considerations for:

  • Donor selection
  • Original cell sourcing
  • Reprogramming methodology
  • Culture and expansion
  • Testing and banking

Characteristics of a Good Cell Donor

An ideal cell donor possesses several key characteristics:

  1. HLA Match
  2. Absence of genetic disorders
  3. Absence of infectious diseases
  4. Highly proliferative cells
  5. Easily genetically manipulable cells
  6. Younger donor: Benefits include fewer accumulated environmental genetic mutations and higher cell proliferation capacity.
  7. Fully informed consent and traceability documentation: Crucial for ethical and legal compliance.
  8. Availability for repeat donation

Ethical and Traceability Considerations: The Case of Henrietta Lacks

The importance of fully informed consent and traceability documentation is underscored by historical cases such as that of Henrietta Lacks (1920–1951).

  • Henrietta Lacks, an African American woman, was treated for cervical cancer at Johns Hopkins Hospital in Baltimore in 1951. During her treatment, doctors took a biopsy of her tumor without her knowledge or consent, a practice that was unfortunately common at the time.
  • Cells derived from her tumor became the first immortal human cell line, famously known as HeLa cells (named from Henrietta Lacks).
  • HeLa cells were groundbreaking because, unlike normal human cells, they could divide indefinitely in culture.
  • They proved essential for a vast array of biomedical research, contributing to the development of the polio vaccine, cancer studies, gene mapping, and even space research.

The Hayflick Limit and HeLa Cell Immortality

Most human cells are not immortal due to a built-in limitation known as the Hayflick limit, typically allowing approximately 40–60 cell divisions. This limit occurs because:

  • Telomeres, the protective caps at the ends of chromosomes, progressively shorten with each cell division.
  • Eventually, telomere shortening triggers the cell to enter senescence (a state of permanent growth arrest) or undergo apoptosis (programmed cell death).

Henrietta's cervical cancer cells, however, exhibited several unique features that conferred their immortality:

  • HPV (Human Papillomavirus) infection: She was infected with a high-risk strain of HPV-18. The viral proteins E6 and E7 effectively inactivate the cell's tumor suppressors, p53 and Rb. This deactivates the normal "stop signals" for cell growth.
  • Telomerase reactivation: Her cancer cells reactivated telomerase, an enzyme responsible for rebuilding telomeres. This prevented the usual telomere shortening, enabling continuous cell divisions.
  • Chromosomal instability: HeLa cells are aneuploid, meaning they possess an abnormal number of chromosomes. This genomic instability played a role in their rapid growth and adaptability in cell culture environments.

(Another notable ethical challenge example mentioned is the Hwang Woo Suk cloning scandal.)

Reprogramming Methodologies: Challenges and Approaches

Yamanaka Integrating Viral Transfection (Disadvantages)

While groundbreaking, initial Yamanaka integrating viral transfection methods present several challenges for clinical use:

  1. Oncogenic potential: Factors like c-Myc and Oct4 are associated with tumorigenicity. For example, in one study, 24 of 121 F1 mice derived from iPSCs died or were euthanized due to health issues, with necropsy of 18 revealing tumors caused by reactivation of c-Myc (Okita et al., 2007).
  2. Insertional mutagenesis: The random integration of viral vectors into the host genome can disrupt essential genes or activate oncogenes.
  3. Lack of copy number control: It is difficult to precisely control the number of viral copies that integrate into the genome.
  4. Immune responses: Viruses can stimulate both innate and adaptive immune responses in the recipient.

Non-Integrating Viral Transfection and Self-Excising Vectors (Disadvantages)

These approaches attempt to address integration concerns but introduce their own problems:

  • Non-integration viral transfection (e.g., Adenoviral and Sendai viruses):

    1. Can still activate innate and adaptive immune responses.

  • Self-excising vectors (using recombinases or transposases):

    1. Incomplete or inefficient excision: Residual vector DNA can remain.
    2. Genomic instability: The excision process often involves double-strand DNA breaks (DSBs), which could lead to genomic instability.
    3. Off-target recombination: Recombinase enzymes (e.g., Cre) can perform off-target recombination, resulting in unintended deletions and rearrangements in the genome (similar to off-target effects seen with CRISPR).
    4. Immune responses: Bacterial recombinases (like Cre) or piggyBac transposases may trigger innate immune responses.

Non-Integrating Non-Viral Approaches (Pros & Cons)

These methods are generally preferred for clinical applications due to their improved safety profiles.

Episomal Plasmids
  • Description: Circular, non-integrating DNA vectors that carry and express reprogramming genes (e.g., OCT4, SOX2, KLF4, c-MYC). They are delivered via transfection.
    • Transfection: Process of introducing nucleic acids (DNA or RNA) into eukaryotic cells using non-viral methods.
    • Transduction: Process of introducing nucleic acids into eukaryotic cells using viral infection methods.
    • Note: Episomal vectors can be delivered virally or non-virally.
  • Delivery Methods:
    • Chemical methods: Utilize lipids (lipofection) or calcium phosphate to encapsulate and deliver DNA.
    • Physical methods: Include electroporation (applying electrical pulses to create temporary pores in the cell membrane) or microinjection (directly injecting DNA with a needle).
  • Pros:
    • No genomic integration.
    • Simple and widely utilized.
  • Cons:
    • Moderate reprogramming efficiency.
    • May necessitate multiple transfection rounds.
    • Plasmid dilution occurs over time as cells divide.
Synthetic mRNA
  • Description: Modified mRNA transcripts encoding reprogramming factors, delivered daily via transfection for 1–2 weeks. These mRNA constructs often include chemical modifications to enhance stability, reduce immune activation, and improve translation efficiency compared to natural mRNA.
  • Pros:
    • High reprogramming efficiency.
    • No manipulation of genomic DNA.
    • Transient and repeatable expression of factors.
  • Cons:
    • Labor-intensive, requiring daily transfections.
    • Transfection procedures can be cytotoxic.
    • mRNA molecules are susceptible to degradation.
Synthetic Protein
  • Description: Purified transcription factor proteins (e.g., OCT4, SOX2) are fused to cell-penetrating peptides (CPPs). The positively-charged amino acid residues of the CPPs interact with the negatively-charged cell membrane, facilitating protein uptake into the cytosol via endocytosis.
  • Pros:
    • Extremely safe, as no genetic material (DNA or RNA) is involved.
    • Eliminates any risk of integration.
  • Cons:
    • Very low reprogramming efficiency.
    • Challenging to produce and purify proteins at a large scale.
    • Transient effect, mandating frequent delivery of the proteins.

Good Manufacturing Practices (GMP) and Clinical Compliance

For cell-based products used in human therapy, adherence to strict guidelines is critical:

  • Products must be established under GMP (Good Manufacturing Practice) conditions in facilities holding a relevant product manufacturing license and operating under rigorous quality assurance.
  • All ethical and legal requirements must be met during generation.
  • iPSC lines serve as crucial intermediate products for numerous emerging cell therapies.

While some hiPSC lines are fully generated under GMP-compliant manufacturing processes, it's common for many ongoing clinical trials to utilize hiPSCs initially generated in non-GMP settings. These lines are subsequently qualified for GMP use through conversion to GMP conditions and additional testing. Key requirements for clinically compliant iPSCs include:

  • Full traceability of the manufacturing process.
  • Use of xeno-free (free of animal-derived components) and clinical-grade reagents.
  • Employment of integration-free methods of reprogramming.

The Kuebler et al. (2023) Study: A Spanish iPSC Haplobank

Big Picture Question

The overarching question addressed by Kuebler et al. is: Can a clinical-grade bank of HLA-homozygous iPSCs be generated to provide high immunological coverage for the Spanish population?

Cord Blood (CB) as the Cell Source

The authors specifically chose cord blood (CB) cells as the optimal source for generating homozygous HLA haplotype hiPSC collections for clinical translation, based on several compelling reasons:

  • (i) Safety: There is no risk to either the mother or the newborn during cord blood collection.
  • (ii) Donor Screening: Cord blood units stored in cord blood banks are typically already HLA typed, which significantly simplifies the donor screening process.
  • (iii) Cell quality: Cord blood cells are less likely to have accumulated genetic or epigenetic risks compared to adult and differentiated cells, as they originate from baby tissue.
  • (iv) Established methodology: The methodology for generating hiPSCs from CB samples is well-established.

Reprogramming Methodology in the Study

Kuebler et al. generated the first clinical-grade iPSC haplobank in Spain by reprogramming CD34+ cells from seven cord blood units, which were chosen for their homozygosity for the most common HLA haplotypes in Spain. The reprogramming was performed using Sendai viral transduction (specifically, Cytotune-iPS 2.0 and 2.1 Sendai Reprogramming Kits) under different multiplicities of infection (MOIs), with no significant changes in reprogramming efficiency observed.

Sendai Virus Vector Details:

  • The Sendai virus is a non-pathogenic, single-stranded RNA virus.
  • It has high transfection (transduction) efficiency across many tissues.
  • Crucially, it lacks a DNA intermediate, thereby eliminating the risk of unwanted DNA integration into the host genome, aligning with the "integration-free" requirement for clinical applications.

These haplolines were subsequently expanded and banked using GMP-compliant methods, intending for their use as clinical-grade intermediates in advanced therapy medicinal product development.

Characterization of iPSC Lines: The iPSC Checklist

To confirm the quality and pluripotency of the generated iPSC lines, the authors performed a comprehensive characterization, adhering to key elements of the iPSC checklist:

Confirmation of Haplotype and Biometrics (Table 1)

The authors successfully confirmed the specific HLA-A, -B, -C, -DRB1, -DQB1, -DPB1 haplotypes, ABO blood type, and sex for each of the seven established iPSC lines (e.g., CD34 iPS1-Sv4F-B8, Hz 30-18-3 CBIPS2-Sv4F-D10, etc.), establishing their basic biometrics.

Population Coverage Assessment (Figure 1)

They assessed the cumulative coverage of the Spanish population achievable with their seven haplolines. This involved modeling coverage without any mismatches (0MM) in HLA-A, HLA-B, and HLA-DRB1, or allowing one (1MM) or two (2MM) mismatches in these loci, thereby determining the practical utility of their haplobank.

CD34+ Cell Expansion and Reprogramming Efficiency (Table 2)

The study quantified the expansion rate of CD34+ cord blood cells prior to reprogramming and determined the reprogramming efficiency for each iPSC clone generated. This included measuring cell numbers at Day 1 and Day 4 and calculating the expansion factor, alongside the final reprogramming efficiency for each clone (e.g., 0.86\% for Hz 29-44-7 CBIPS1 Sv4F-B8, 1.8\% for Hz 30-18-3 CBIPS2 Sv4F-D10, etc.).

Morphological Assessment (Figure 2, Phase Contrast)

Phase contrast microscopy images of the iPSC clones (B8, D10, E9, F6, H6, I12, J1) were analyzed to confirm that the putative iPSCs exhibited characteristic pluripotent stem cell morphology, including:

  • Dense colony expansion.
  • "Cobblestone" morphology.
  • High nucleus-to-cytoplasm ratio.
  • Presence of large nucleoli.

Absence of Sendai Virus Transgenes (Figure S1)

Through PCR analysis of genomic DNA (gDNA) extracted from iPSC clones at various passages (e.g., B6 at passage 20, D10 at passage 19), the authors confirmed the absence of the Sendai virus genome and its specific transgenes (like the polycistronic Klf4-Oct3/4-Sox2 cassette). This is a critical check for ensuring integration-free reprogramming, utilizing positive controls (sample with SeV) and negative controls (sample without RT, sample without SeV infection, H2O) to validate the assay's accuracy.

Karyotypic Stability (Figure S2)

G-Banding karyotypes of representative metaphases from the iPSC lines (e.g., B6 at passage 22, D10 at passage 21) were performed. These analyses demonstrated diploid 46, XX or XY karyotypes without any detectable chromosomal abnormalities. This assessment is vital because genomic integrity is paramount for clinical safety, as abnormalities could impact differentiation, lead to tumor formation, or render cells unsuitable for therapy.

Protein Expression of Pluripotency Markers (Figure 2, Immunocytochemistry)

Immunocytochemistry (ICC) was employed to confirm the expression of key pluripotent stem cell markers at the protein level. ICC is a technique that detects specific proteins or antigens within individual cells using antibodies. It is distinct from immunohistochemistry (IHC) in that it is applied to cultured cells rather than tissue sections. The iPSC lines showed positive expression for markers such as NANOG, TRA-1-81, OCT4, SSEA3, SOX2, SSEA4, and TRA-1-60.

Functional Pluripotency: Embryoid Body Differentiation (Figure 3)

The authors demonstrated the functional pluripotency of their iPSC lines through Embryoid Body (EB) differentiation. EB differentiation is an in vitro technique that induces spontaneous, multi-lineage differentiation of pluripotent stem cells (PSCs) into cell types derived from all three germ layers: ectoderm, mesoderm, and endoderm.

  • Mechanism: EBs are 3D cell aggregates formed when PSCs are cultured in suspension, mimicking the structure and signaling of an early post-implantation embryo.
  • Results: Immunofluorescence staining of differentiated EBs confirmed the presence of all three germ layers:
    • Endoderm: Expressing markers such as AFP and FOXA2.
    • Mesoderm: Expressing markers like ASMA and GATA4.
    • Ectoderm: Expressing markers such as TUJ1 and GFAP.

Other Functional Pluripotency Assays (for context):

  • Teratoma Assay: A functional test of pluripotency performed in vivo. PSCs are injected into immunodeficient mice (e.g., NOD/SCID), forming a benign tumor-like mass (teratoma) in 4–8 weeks. Histological analysis of the excised tumor confirms differentiation into tissues representing all three germ layers (e.g., neural rosettes for ectoderm, cartilage for mesoderm, gut-like epithelium for endoderm).
  • Chimera Assay: The most stringent in vivo test of pluripotency. Labeled PSCs are injected into a developing embryo (typically a blastocyst), which is then implanted into a pseudopregnant mother. The resulting chimeric organism is analyzed for donor cell contribution to all tissues, including the germline.

Quality Control for Clinical-Grade Cell Banks (Table 3)

To ensure the suitability of the iPSC lines for clinical use, rigorous quality control (QC) assays were performed on both the Master Cell Bank (MCB) and Working Cell Bank (WCB) production runs, adhering to predefined acceptance criteria:

  • Sterility (Ph. Eur. 2.6.27): Negative.
  • Mycoplasma (Ph. Eur. 2.6.7): Negative.
  • Endotoxin (Ph. Eur. 2.6.14): <5 EU/mL.
  • Adventitious viruses (cytopathic culture): Negative.
  • Viability upon freezing (7AAD negative): >50\%.
  • Recovery 7 days upon thawing: >20 colonies or 50\% confluence.
  • Total cell number before freezing (Neubauer): >1 \times 10^6 cells/vial.
  • Viability by dye exclusion cytometry (7AAD): \ge 50\% 7AAD-.

These extensive QC measures confirm that all production runs comply with the necessary standards for sterility, cell number, and viability, which are essential for clinical-grade material.

Broader Challenges in Cell Therapy Development

Developing cell therapies in regions like the US or UK can present different challenges compared to countries like China or South Korea. These differences often stem from varying regulatory frameworks, ethical considerations, speed of approval processes, and potentially cost structures. Regulatory bodies in Western countries often have stringent approval pathways and high standards for clinical trials, focusing on extensive safety and efficacy data, which can slow down product development. Ethical oversight can also be more complex. In some Eastern countries, there might be different regulatory approaches or accelerated pathways, sometimes leading to faster translation of research to clinical application, though the underlying ethical and safety considerations remain paramount globally.